je.st
news
Trigemina Presents Data On Intranasal Oxytocin For The Treatment Of Trigeminal Neuralgia
2013-09-04 06:35:32| drugdiscoveryonline News Articles
Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, announced that David C. Yeomans, Ph.D., Chief Scientist and Founder of Trigemina, as well as the Director of Pain Research at Stanford University School of Medicine, presented at the 2013 Napa Pain Conference on August 23rd – 25th, 2013 in Napa, California
Tags: data
treatment
presents
intranasal
Category:Biotechnology and Pharmaceuticals